Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rapamycin formulation offers hope for rare polyp disorder

NCT ID NCT07689942

AVAILABLE Disease control Sponsor: Biodexa Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This expanded access program provides eRapa, an oral encapsulated form of rapamycin, to people with familial adenomatous polyposis (FAP) who have no good treatment options and cannot join a clinical trial. FAP causes hundreds of polyps in the colon and rectum, raising cancer risk. The goal is to offer potential benefit under careful monitoring for safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
eRapa (encapsulated rapamycin)
What this could lead to
If it works, this could help control polyp growth in people with familial adenomatous polyposis, potentially delaying or avoiding surgery.
What could go wrong
This is an expanded access program, not a formal trial, so evidence is limited. Rapamycin can cause side effects like mouth sores, infections, and metabolic changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL ADENOMATOUS POLYPOSIS (FAP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenomatous Polyposis Coli classic familial adenomatous polyposis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAMILIAL ADENOMATOUS POLYPOSIS (FAP)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.